Cinqualbre J.,Hopitaux Universitaires Of Strasbourg |
Kientz D.,EFS Alsace |
Remy E.,EFS Alsace |
Huang N.,Cerus Corporation |
And 2 more authors.
Transfusion | Year: 2015
BACKGROUND Liver transplant may require large-volume plasma transfusion with increased risk of transfusion-transmitted infection (TTI). Pathogen inactivation of plasma with amotosalen-UVA offers the potential to mitigate TTI risk. STUDY DESIGN AND METHODS A retrospective cohort design was used to compare the therapeutic efficacy and key safety outcomes for liver transplants supported with quarantine plasma (Q-FFP [reference]) or amotosalen-UVA plasma (IBS plasma [test]). The outcomes evaluated were volume of plasma, the numbers of red blood cell (RBC) components, and the total dose of platelets (PLTs) transfused during and 7 days after transplant. The safety outcomes were acute hepatic artery thrombosis (HAT) and mortality. RESULTS Transplantation and transfusion records for 212 Q-FFP transplants and 215 IBS plasma transplants were reviewed. Not all transplants required plasma; 161 received Q-FFP and 174 received IBS plasma. Among the transplants that required plasma, there were significant differences in median values between cohorts for delay to transplantation (p=0.002), model end-stage liver disease score (p<0.001), pretransplant hematocrit (p=0.006), and graft cold perfusion time (p=0.033). The median volumes of plasma transfused were not different for test and reference (2.160 L vs. 1.969 L, p=0.292). Transplants in the test cohort required a mean of 3.7% more RBC components (p=0.767) and on average a 16.5% increase in total PLT dose (p=0.518). No significant differences were observed for the frequency of acute HAT or mortality. CONCLUSION In this retrospective study, IBS plasma provided therapeutic support of liver transplant not different from Q-FFP. © 2015 Cerus Corporation. Transfusion published by Wiley Periodicals, Inc. on behalf of AABB.
Froelich N.,EFS Alsace |
Weschler B.,EFS Alsace |
Hanau D.,EFS Alsace |
Hanau D.,French Institute of Health and Medical Research |
And 3 more authors.
Tissue Antigens | Year: 2011
Two new HLA-C alleles were identified in a volunteer bone marrow donor by sequence-based typing. © 2011 John Wiley & Sons A/S.
David T.,EFS Alsace |
David T.,French Institute of Health and Medical Research |
David T.,University of Strasbourg |
Strassel C.,EFS Alsace |
And 14 more authors.
Journal of Thrombosis and Haemostasis | Year: 2010
Background: Circulating platelets are initially recruited at the site of vessel injury by von Willebrand factor (VWF) immobilized on collagen fibers. This process, mediated by the GPIb-V-IX complex, is accompanied by specific intracellular signaling leading to reorganization of the platelet actin cytoskeleton and extension of filopodia. Objectives/methods: To evaluate the GPIbα and GPIbβ intracellular domains contribution to this signaling, we generated Chinese hamster ovary (CHO) cells expressing a GPIb-IX complex with mutant forms of the two subunits and we measured their ability to extend filopodia upon adhesion on a VWF matrix. Results: Complete intracellular deletion or elimination of the filamin or the 14-3-3ζ binding sites in GPIbα did not prevent filopodia extension. In contrast, deletion of the juxtamembrane (Leu150-Arg160) or central (Ala159-Pro170) intracellular segment of GPIbβ resulted in a 21% and 23% reduction in the number of cells extending filopodia, respectively. This occurred without decreasing adhesion efficiency or GPIb-IX association with filamin A or 14-3-3ζ. Alanine scanning mutagenesis of the Leu150-Pro170 segment identified Arg164, Leu165, Leu167, Thr168 and Pro170 as important residues for efficient filopodia formation. Surprisingly, mutation of the Ser166 PKA phosphorylation site did not alter adhesion and shape change. A role for the GPIbβ subunit was reinforced by the decreased capacity to extend filopodia upon adhesion on VWF of platelets from knock-in mice expressing a GPIbβ intracellular deletion mutant. Conclusions: Altogether, our results strongly support participation of GPIbβ and its intracellular region in GPIb-dependent platelet activation and shape change triggered by a VWF matrix. © 2009 International Society on Thrombosis and Haemostasis.
Cazenave J.-P.,EFS Alsace |
Cazenave J.-P.,Cerus Corporation |
Cazenave J.-P.,Catholic University of Louvain |
Waller C.,EFS Alsace |
And 35 more authors.
Transfusion | Year: 2010
BACKGROUND: Photochemical pathogen inactivation treatment (PCT) of plasma components with amotosalen and UVA has been implemented in Europe. To establish a postapproval safety database, an active hemovigilance (HV) program utilizing an electronic data capture system (EDCS) was initiated. STUDY DESIGN AND METHODS: The response to transfusion was documented after each PCT-plasma transfusion. The primary outcome was the incidence of acute transfusion reactions (ATRs) within 24 hours of transfusion. An ATR was defined as an adverse event (AE) possibly related, probably related, or related to the PCT-plasma transfusion. For AEs, the following were collected: time of event after transfusion, clinical description, vital signs, clinical and laboratory test results, severity (Grade 0-4), seriousness, and causal relationship to transfusion of PCT-plasma. RESULTS: To date, 3232 patients (59.1% male) with a primary indication for plasma transfusion due to a hematology disorder (23.1%), surgery (32.4%), or a general medical condition (44.4%) received 7483 PCT-plasma transfusions (composed of 19,069 apheresis plasma components). The mean age of the patient population was 57.3 years (2884 adults, 160 children, and 188 infants). ATRs were reported for 8/7483 transfusions (0.11%; 95% confidence interval [CI], 0.03-0.19) and 8/3232 patients (0.25%; 95% CI, 0.08-0.42%). Five ATRs were of Grade 1 severity. The remaining three ATRs were classified as serious. No deaths or episodes of transfusion-related acute lung injury attributed to a PCT-plasma transfusion were reported. CONCLUSION: PCT-plasma transfusions were well tolerated in routine clinical use. The EDCS HV program facilitated collection and reporting of safety information on a real-time basis from multiple sites. © 2010 American Association of Blood Banks.